Peach Megan L, Cachau Raul E, Nicklaus Marc C
Basic Science Program, Chemical Biology Laboratory, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Data Science and Information Technology Program, Advanced Biomedical Computing Center, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
J Mol Recognit. 2017 Aug;30(8). doi: 10.1002/jmr.2618. Epub 2017 Feb 24.
In this review, we address a fundamental question: What is the range of conformational energies seen in ligands in protein-ligand crystal structures? This value is important biophysically, for better understanding the protein-ligand binding process; and practically, for providing a parameter to be used in many computational drug design methods such as docking and pharmacophore searches. We synthesize a selection of previously reported conflicting results from computational studies of this issue and conclude that high ligand conformational energies really are present in some crystal structures. The main source of disagreement between different analyses appears to be due to divergent treatments of electrostatics and solvation. At the same time, however, for many ligands, a high conformational energy is in error, due to either crystal structure inaccuracies or incorrect determination of the reference state. Aside from simple chemistry mistakes, we argue that crystal structure error may mainly be because of the heuristic weighting of ligand stereochemical restraints relative to the fit of the structure to the electron density. This problem cannot be fixed with improvements to electron density fitting or with simple ligand geometry checks, though better metrics are needed for evaluating ligand and binding site chemistry in addition to geometry during structure refinement. The ultimate solution for accurately determining ligand conformational energies lies in ultrahigh-resolution crystal structures that can be refined without restraints.
在本综述中,我们探讨一个基本问题:在蛋白质-配体晶体结构中,配体所见的构象能范围是多少?该值在生物物理学上很重要,有助于更好地理解蛋白质-配体结合过程;在实际应用中,可为对接和药效团搜索等多种计算药物设计方法提供一个参数。我们综合了此前关于此问题的计算研究中一些相互矛盾的结果,并得出结论:在某些晶体结构中确实存在高配体构象能。不同分析之间存在分歧的主要根源似乎在于对静电作用和溶剂化的不同处理方式。然而,与此同时,对于许多配体而言,由于晶体结构不准确或参考状态的确定有误,高配象能是错误的。除了简单的化学错误外,我们认为晶体结构错误可能主要是由于相对于结构与电子密度的拟合,对配体立体化学限制进行了启发式加权。尽管在结构精修过程中,除了几何结构外,还需要更好的指标来评估配体和结合位点的化学性质,但这个问题无法通过改进电子密度拟合或简单的配体几何结构检查来解决。准确确定配体构象能的最终解决方案在于无需限制即可精修的超高分辨率晶体结构。